Compare Repligen Corporation Common Stock (RGEN) vs State Street Corporation Common Stock (STT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs State Street Corporation Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while State Street Corporation Common Stock trades at $167.94 (market cap $47.83B). The key difference: State Street Corporation Common Stock is far larger — about 4.3× Repligen Corporation Common Stock's market cap, and State Street Corporation Common Stock pays a 2.11% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and State Street Corporation Common Stock for 2 Days on average.
| RGEN | STT | |
|---|---|---|
Market Cap | $11.14B | $47.83B |
Volume | 1,259,263 | 2,907,463 |
Sector | Health | Financials |
52-Week High | $194.57 | $194.26 |
52-Week Low | $102.87 | $111.37 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.02B | $74.34B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →
